RxDoctor Payments Data

Maria Comsti, MD

Internal Medicine · Neptune, NJNPI 1376501866

Payments from drug & device makers

$995in general payments, 2019–2025

Across 61 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$197
  • Lilly USA, LLC$155
  • Astellas Pharma US Inc$131
  • Exact Sciences$103
  • Boehringer Ingelheim$71
  • Philips North America LLC$57
  • plus $280 from 11 others

What the payments were for

  • Food & beverage$91592%
  • Education$808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$995 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,778
Medicare patients
160
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate63$58,598
FarxigaDapagliflozin Propanediol26$25,349
EliquisApixaban12$16,015
OzempicSemaglutide12$14,712
Janumet XrSitagliptin Phos/Metformin Hcl12$12,677
JardianceEmpagliflozin16$11,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$9,015
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,901
BreynaBudesonide/Formoterol Fumarate12$2,698
Olmesartan Medoxomil31$2,470
Rosuvastatin Calcium132$2,388
Albuterol Sulfate HfaAlbuterol Sulfate83$2,233
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,205
Atorvastatin Calcium171$2,044
Glipizide135$1,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$28$71,27575 claims
AstraZenecaFarxiga$197$25,34926 claims
PfizerEliquis$39$16,01512 claims
Novo NordiskOzempic$43$14,71212 claims
Boehringer IngelheimJardiance$71$11,85816 claims
AbbVieSynthroid$25$1,04817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →